{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:03:32Z","timestamp":1771275812225,"version":"3.50.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Accord Healthcare, Munich, Germany"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00520-026-10354-1","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T02:37:18Z","timestamp":1769308638000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of pegylated filgrastim (Pelgraz\u00ae) for the prevention of febrile neutropenia during cancer chemotherapy in all-day practice in Germany"],"prefix":"10.1007","volume":"34","author":[{"given":"Tilman","family":"Steinmetz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Jungberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagmar","family":"Guth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Knoblich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Fietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"G\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel","family":"Reiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Totzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"10354_CR1","doi-asserted-by":"publisher","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for R, Treatment of C (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"10354_CR2","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1093\/annonc\/mdw309","volume":"27","author":"M Aapro","year":"2016","unstructured":"Aapro M, Ludwig H, Bokemeyer C, Gasc\u00f3n P, Boccadoro M, Denhaerynck K, Krendyukov A, Gorray M, MacDonald K, Abraham I (2016) Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol 27:2039\u20132045. https:\/\/doi.org\/10.1093\/annonc\/mdw309","journal-title":"Ann Oncol"},{"key":"10354_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.13034","volume":"28","author":"M Aapro","year":"2019","unstructured":"Aapro M, Krendyukov A, H\u00f6bel N, Gascon P (2019) Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced\/febrile neutropaenia: results from the MONITOR-GCSF study. Eur J Cancer Care (Engl) 28:e13034. https:\/\/doi.org\/10.1111\/ecc.13034","journal-title":"Eur J Cancer Care (Engl)"},{"key":"10354_CR4","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1200\/jco.2012.48.3644","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Grutters JP, Peters PF, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Joore MA, Borm GF, Tjan-Heijnen VC (2013) Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 31:4283\u20134289. https:\/\/doi.org\/10.1200\/jco.2012.48.3644","journal-title":"J Clin Oncol"},{"key":"10354_CR5","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1200\/jco.2012.44.6229","volume":"31","author":"MJ Aarts","year":"2013","unstructured":"Aarts MJ, Peters PF, Mandigers CM, Dercksen MW, Stouthard JM, Nortier HJ, van Laarhoven HW, van Warmerdam LJ, van de Wouw AJ, Jacobs EM, Mattijssen V, van der Rijt CC, Smilde TJ, van der Velden AW, Temizkan M, Batman E, Muller EW, van Gastel SM, Borm GF, Tjan-Heijnen VC (2013) Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia. J Clin Oncol 31:4290\u20134296. https:\/\/doi.org\/10.1200\/jco.2012.44.6229","journal-title":"J Clin Oncol"},{"key":"10354_CR6","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00520-018-4522-5","volume":"27","author":"CN Abboud","year":"2019","unstructured":"Abboud CN, Lang N, Fung H, Lammerich A, Buchner A, Liu P, Mueller U, Pettengell R, Diel IJ, Link H, Pathak A (2019) Real-world safety experience of tevagrastim\/ratiograstim\/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors. Support Care Cancer 27:2569\u20132577. https:\/\/doi.org\/10.1007\/s00520-018-4522-5","journal-title":"Support Care Cancer"},{"key":"10354_CR7","volume-title":"Practical statistics for medical research","author":"D Altman","year":"1991","unstructured":"Altman D (1991) Practical statistics for medical research. Chapman and Hall, London"},{"key":"10354_CR8","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.3747\/co.20.1306","volume":"20","author":"AK Altwairgi","year":"2013","unstructured":"Altwairgi AK, Hopman WM, Mates M (2013) Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia. Curr Oncol 20:e171-179. https:\/\/doi.org\/10.3747\/co.20.1306","journal-title":"Curr Oncol"},{"key":"10354_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/oncolo\/oyac074","volume":"27","author":"R Boccia","year":"2022","unstructured":"Boccia R, Glaspy J, Crawford J, Aapro M (2022) Chemotherapy-induced neutropenia and febrile neutropenia in the US: a beast of burden that needs to be tamed? Oncologist 27:625\u2013636. https:\/\/doi.org\/10.1093\/oncolo\/oyac074","journal-title":"Oncologist"},{"key":"10354_CR10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00520-017-3572-4","volume":"25","author":"C Bokemeyer","year":"2017","unstructured":"Bokemeyer C, Gasc\u00f3n P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K (2017) Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study. Support Care Cancer 25:1819\u20131828. https:\/\/doi.org\/10.1007\/s00520-017-3572-4","journal-title":"Support Care Cancer"},{"key":"10354_CR11","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1080\/14796694.2024.2349510","volume":"20","author":"M Borgeaud","year":"2024","unstructured":"Borgeaud M, Perano S, Addeo A, Tsantoulis P (2024) Rates of febrile neutropenia and its causes in the real world. Future Oncol 20:2203\u20132212. https:\/\/doi.org\/10.1080\/14796694.2024.2349510","journal-title":"Future Oncol"},{"key":"10354_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/17474086.2022.2093712","volume":"15","author":"K Campbell","year":"2022","unstructured":"Campbell K, Chadha N, Dimri S, Wang W, Li E (2022) G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review. Expert Rev Hematol 15:619\u2013633. https:\/\/doi.org\/10.1080\/17474086.2022.2093712","journal-title":"Expert Rev Hematol"},{"key":"10354_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/17843286.2018.1563735","volume":"75","author":"G Catala","year":"2020","unstructured":"Catala G, Mebis J, Jerusalem G, Verhoeven D, Awada A, Bols A, Somers L, Van Den Broeck A, Duhoux FP, Machiels JP (2020) Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. Acta Clin Belg 75:128\u2013135. https:\/\/doi.org\/10.1080\/17843286.2018.1563735","journal-title":"Acta Clin Belg"},{"key":"10354_CR14","doi-asserted-by":"publisher","first-page":"6895","DOI":"10.21037\/tcr-24-2035","volume":"13","author":"G Cheng","year":"2024","unstructured":"Cheng G, Chen Y, Xu N, Mao C, Zhang N, Chen M, Yan H, Yang Z, Bie J, Ding L, Wang Z, Yan J, Cariati P, Qin S (2024) Safety and efficacy of mecapegfilgrastim in preventing neutropenia in patients with head and neck cancer: a multicenter, prospective, observational, real-world study. Transl Cancer Res 13:6895\u20136904. https:\/\/doi.org\/10.21037\/tcr-24-2035","journal-title":"Transl Cancer Res"},{"key":"10354_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00520-017-3854-x","volume":"26","author":"DC Dale","year":"2018","unstructured":"Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH (2018) A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 26:7\u201320. https:\/\/doi.org\/10.1007\/s00520-017-3854-x","journal-title":"Support Care Cancer"},{"key":"10354_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clml.2017.05.002","volume":"17","author":"GL Damaj","year":"2017","unstructured":"Damaj GL, Benbrahim O, Hacini M, Voronina I, Benabed K, Soumoudronga RF, Gasnereau I, Haioun C, Solal-C\u00e9ligny P (2017) ZOH\u00e9:a prospective study of the use of biosimilar filgrastim Zarzio in clinical practice in patients treated with chemotherapy for lymphoid malignancies. Clin Lymphoma Myeloma Leuk 17:362-369 e362. https:\/\/doi.org\/10.1016\/j.clml.2017.05.002","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10354_CR17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD (2013) Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 31:794\u2013810. https:\/\/doi.org\/10.1200\/JCO.2012.45.8661","journal-title":"J Clin Oncol"},{"key":"10354_CR18","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00520-015-2861-z","volume":"24","author":"P Gasc\u00f3n","year":"2016","unstructured":"Gasc\u00f3n P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, Denhaerynck K, MacDonald K, Abraham I (2016) Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer 24:911\u2013925. https:\/\/doi.org\/10.1007\/s00520-015-2861-z","journal-title":"Support Care Cancer"},{"key":"10354_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000512594","volume":"44","author":"C Gessner","year":"2021","unstructured":"Gessner C, Potthoff K, Frost N (2021) Efficacy and safety of lipegfilgrastim in lung cancer patients receiving myelosuppressive chemotherapy in a real-world setting: results of an analysis of pooled data from two non-interventional european studies. Oncol Res Treat 44:93\u2013102. https:\/\/doi.org\/10.1159\/000512594","journal-title":"Oncol Res Treat"},{"key":"10354_CR20","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1080\/03007995.2022.2113693","volume":"38","author":"C Gessner","year":"2022","unstructured":"Gessner C, Fietz T, Losem C, L\u00fcck A, Schulz H, Niemeier B, Groschek M, Eschenburg H, Weide R, Kretzschmar A, Frost N, Hipp J, Harde J, Matillon CD, Grebhardt S, Potthoff K (2022) Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR. Curr Med Res Opin 38:2191\u20132199. https:\/\/doi.org\/10.1080\/03007995.2022.2113693","journal-title":"Curr Med Res Opin"},{"key":"10354_CR21","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1007\/s00277-017-3098-3","volume":"96","author":"WJ Heinz","year":"2017","unstructured":"Heinz WJ, Buchheidt D, Christopeit M, von Lilienfeld-Toal M, Cornely OA, Einsele H, Karthaus M, Link H, Mahlberg R, Neumann S, Ostermann H, Penack O, Ruhnke M, Sandherr M, Schiel X, Vehreschild JJ, Weissinger F, Maschmeyer G (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96:1775\u20131792. https:\/\/doi.org\/10.1007\/s00277-017-3098-3","journal-title":"Ann Hematol"},{"key":"10354_CR22","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1007\/s00520-022-07265-2","volume":"30","author":"A Jenabian","year":"2022","unstructured":"Jenabian A, Ehsanpour A, Mortazavizadeh SMR, Raafat J, Razavi M, Khosravi A, Seifi S, Salimi B, Anjidani N, Kafi H (2022) Evaluating the safety and effectiveness of PegaGen(\u00ae) (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study. Support Care Cancer 30:8151\u20138158. https:\/\/doi.org\/10.1007\/s00520-022-07265-2","journal-title":"Support Care Cancer"},{"key":"10354_CR23","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.2217\/fon-2022-0365","volume":"18","author":"K Kitchen","year":"2022","unstructured":"Kitchen K, Mosier MC (2022) Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy. Future Oncol 18:2551\u20132560. https:\/\/doi.org\/10.2217\/fon-2022-0365","journal-title":"Future Oncol"},{"key":"10354_CR24","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, Committee EG (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27:v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"10354_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00520-014-2597-1","volume":"23","author":"Y Kosaka","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y, Tamura K (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer 23:1137\u20131143. https:\/\/doi.org\/10.1007\/s00520-014-2597-1","journal-title":"Support Care Cancer"},{"key":"10354_CR26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000381631","volume":"38","author":"CM Kurbacher","year":"2015","unstructured":"Kurbacher CM, Fietz T, Diel IJ, Egert M, Hurtz HJ, L\u00fcck A, Weide R, Salat C, Wolff T, Zaiss M, Klare P, Losem C, Illmer T, Wei\u00dfenborn G, Steffens CC, Schulze M, Tesch H, Oskay-Oezcelik G, Teichmann B, Harde J, Scheuerlein RW (2015) NADIR: a non-interventional study on the prophylaxis of chemotherapy-induced neutropenia using lipegfilgrastim - first interim analysis. Oncol Res Treat 38:221\u2013229. https:\/\/doi.org\/10.1159\/000381631","journal-title":"Oncol Res Treat"},{"key":"10354_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/op.24.00047","volume":"21","author":"YJ Lee","year":"2025","unstructured":"Lee YJ, Delate T, Hui RL, Le K, Pham C (2025) Real-world noninferiority assessment of two filgrastim biosimilars in patients receiving myelosuppressive chemotherapy. JCO Oncol Pract 21:245\u2013251. https:\/\/doi.org\/10.1200\/op.24.00047","journal-title":"JCO Oncol Pract"},{"key":"10354_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00520-023-08071-0","volume":"31","author":"B Leon Rapoport","year":"2023","unstructured":"Leon Rapoport B, Garcia-Morillo M, Font C, Samoon Z, Jabbar AA, Kourie HR, Kayumba A, Esposito F, Popescu RA, Garc\u00eda-G\u00f3mez J, Heyman L, Smit T, Krendyukov A, Mathieson N, Cooksley T, Anderson R, Klastersky J (2023) A prospective, real-world, multinational study of febrile neutropenia (FN) occurrence in oncology patients receiving chemotherapy with intermediate risk of FN: a MASCC Neutropenia, Infection, and Myelosuppression Study Group initiative. Support Care Cancer 31:628. https:\/\/doi.org\/10.1007\/s00520-023-08071-0","journal-title":"Support Care Cancer"},{"key":"10354_CR29","first-page":"1","volume":"22","author":"R Likert","year":"1932","unstructured":"Likert R (1932) A technique for the measurement of attitudes. Arch Psychol 22:1\u201355","journal-title":"Arch Psychol"},{"key":"10354_CR30","doi-asserted-by":"publisher","first-page":"9317","DOI":"10.1007\/s00520-022-07353-3","volume":"30","author":"H Link","year":"2022","unstructured":"Link H, Thompson SF, Tian M, Haas JS, Meise D, Maas C, Dimitrov S (2022) A comparative assessment of neutropenia events, healthcare resource use, and costs among cancer patients treated with lipegfilgrastim compared with pegfilgrastim in Germany. Support Care Cancer 30:9317\u20139327. https:\/\/doi.org\/10.1007\/s00520-022-07353-3","journal-title":"Support Care Cancer"},{"key":"10354_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2217\/fon-2018-0814","volume":"15","author":"H Ludwig","year":"2019","unstructured":"Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gasc\u00f3n P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K (2019) Chemotherapy-induced neutropenia\/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study. Future Oncol 15:897\u2013907. https:\/\/doi.org\/10.2217\/fon-2018-0814","journal-title":"Future Oncol"},{"key":"10354_CR32","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1007\/s00520-018-4513-6","volume":"27","author":"H Ludwig","year":"2019","unstructured":"Ludwig H, Gasc\u00f3n P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I (2019) Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio\u00ae) initiated \u201csame-day\u201d (< 24 h), \u201cper-guidelines\u201d (24\u201372 h), and \u201clate\u201d (> 72 h): findings from the MONITOR-GCSF study. Support Care Cancer 27:2301\u20132312. https:\/\/doi.org\/10.1007\/s00520-018-4513-6","journal-title":"Support Care Cancer"},{"key":"10354_CR33","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1093\/annonc\/mdt226","volume":"24","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Dale DC, Culakova E, Poniewierski MS, Wolff DA, Kuderer NM, Huang M, Crawford J (2013) The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol 24:2475\u20132484. https:\/\/doi.org\/10.1093\/annonc\/mdt226","journal-title":"Ann Oncol"},{"key":"10354_CR34","doi-asserted-by":"publisher","DOI":"10.21037\/atm-21-2449","volume":"9","author":"J Ma","year":"2021","unstructured":"Ma J, Huang H, Fu P, Xu N, Mao C, Cheng G, Yan H, Li Y, Shi Y, Wang Y, Yao Y, Chen L, Chen Y, Zhang N, Zhang G, Ren Z, Li Z, Song L, Xu R, Qin S (2021) Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies: a real-world study. Ann Transl Med 9:893. https:\/\/doi.org\/10.21037\/atm-21-2449","journal-title":"Ann Transl Med"},{"key":"10354_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/1078155220980517","volume":"28","author":"L Maahs","year":"2022","unstructured":"Maahs L, Tang A, Saheli ZA, Jacob B, Polasani R, Hwang C (2022) Real-world effectiveness of the pegfilgrastim on-body injector in preventing severe neutropenia. J Oncol Pharm Pract 28:17\u201323. https:\/\/doi.org\/10.1177\/1078155220980517","journal-title":"J Oncol Pharm Pract"},{"key":"10354_CR36","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.2217\/fon-2021-0532","volume":"17","author":"A McBride","year":"2021","unstructured":"McBride A, Alrawashdh N, Bartels T, Moore L, Persky D, Abraham I (2021) Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy. Future Oncol 17:3485\u20133497. https:\/\/doi.org\/10.2217\/fon-2021-0532","journal-title":"Future Oncol"},{"key":"10354_CR37","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.18553\/jmcp.2021.21010","volume":"27","author":"A McBride","year":"2021","unstructured":"McBride A, Campbell K, Li E, Schroader B, Campbell D, Wang W (2021) Economic and clinical outcomes of pegfilgrastim via prefilled syringe vs on-body injector: a real-world data analysis. J Manag Care Spec Pharm 27:1230\u20131238. https:\/\/doi.org\/10.18553\/jmcp.2021.21010","journal-title":"J Manag Care Spec Pharm"},{"key":"10354_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655355","volume":"11","author":"AS Merseburger","year":"2021","unstructured":"Merseburger AS, Geiges G, Klier J, Wiesholzer M, Pichler P (2021) Pooled analysis on the effectiveness and safety of lipegfilgrastim in patients with urological malignancies in the real-world setting. Front Oncol 11:655355. https:\/\/doi.org\/10.3389\/fonc.2021.655355","journal-title":"Front Oncol"},{"key":"10354_CR39","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1177\/1078155215625459","volume":"22","author":"S Mitchell","year":"2016","unstructured":"Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M (2016) Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract 22:702\u2013716. https:\/\/doi.org\/10.1177\/1078155215625459","journal-title":"J Oncol Pharm Pract"},{"key":"10354_CR40","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00520-019-05001-x","volume":"28","author":"H Nomura","year":"2020","unstructured":"Nomura H, Hatogai K, Maki Y, Mochizuki N, Tanaka M, Saito S, Daiko H, Kojima T, Kawasaki T (2020) Risk factors for febrile neutropenia in neoadjuvant docetaxel, cisplatin, and 5-fluorouracil chemotherapy for esophageal cancer. Support Care Cancer 28:1849\u20131854. https:\/\/doi.org\/10.1007\/s00520-019-05001-x","journal-title":"Support Care Cancer"},{"key":"10354_CR41","doi-asserted-by":"publisher","first-page":"347","DOI":"10.21873\/anticanres.14782","volume":"41","author":"R Pettengell","year":"2021","unstructured":"Pettengell R, Wolff T, Goehler T, Cascavilla N (2021) Pooled-analysis of lipegfilgrastim effectiveness and safety among patients with blood malignancies in the real-world setting. Anticancer Res 41:347\u2013354. https:\/\/doi.org\/10.21873\/anticanres.14782","journal-title":"Anticancer Res"},{"key":"10354_CR42","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1186\/s12885-018-4986-1","volume":"18","author":"H Roch\u00e9","year":"2018","unstructured":"Roch\u00e9 H, Eymard JC, Radji A, Prevost A, Diab R, Lamuraglia M, Soumoudronga RF, Gasnereau I, Toledano A (2018) Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOH\u00e9 study). BMC Cancer 18:1127. https:\/\/doi.org\/10.1186\/s12885-018-4986-1","journal-title":"BMC Cancer"},{"key":"10354_CR43","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1007\/s00520-018-4473-x","volume":"27","author":"JP Salmon","year":"2019","unstructured":"Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L, Wetten S, O\u2019Kelly J (2019) Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin\u2019s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study. Support Care Cancer 27:1449\u20131457. https:\/\/doi.org\/10.1007\/s00520-018-4473-x","journal-title":"Support Care Cancer"},{"key":"10354_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101214","volume":"51","author":"M Sandherr","year":"2025","unstructured":"Sandherr M, Stemler J, Schalk E, Hattenhauer T, Hentrich M, Hertenstein B, Hohmann C, Mellinghoff SC, Mispelbaum R, Rieger C, Schmidt-Hieber M, Sprute R, Weiss G, Cornely OA, Henze L, Lass-Floerl C, Beutel G, Classen AY, Freise NF, Karthaus M, Koehler P, Krause R, Neuhann J, Orth HM, Penack O, Schaich M, Spiekermann K, Voigt S, Weissinger F, Busch E (2025) 2024 update of the AGIHO guideline on diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients with solid tumours and hematological malignancies. Lancet Reg Health Eur 51:101214. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101214","journal-title":"Lancet Reg Health Eur"},{"key":"10354_CR45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jiac.2017.12.011","volume":"24","author":"K Tamura","year":"2018","unstructured":"Tamura K, Hashimoto K, Nishikawa K (2018) Clinical safety and efficacy of \u201cfilgrastim biosimilar 2\u201d in Japanese patients in a post-marketing surveillance study. J Infect Chemother 24:363\u2013369. https:\/\/doi.org\/10.1016\/j.jiac.2017.12.011","journal-title":"J Infect Chemother"},{"key":"10354_CR46","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston K, Strasfeld L, Flowers CR (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol 36:1443\u20131453. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211","journal-title":"J Clin Oncol"},{"key":"10354_CR47","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1093\/annonc\/mdu035","volume":"25","author":"JJ Vehreschild","year":"2014","unstructured":"Vehreschild JJ, Bohme A, Cornely OA, Kahl C, Karthaus M, Kreuzer KA, Maschmeyer G, Mousset S, Ossendorf V, Penack O, Vehreschild M, Bohlius J (2014) Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO). Ann Oncol 25:1709\u20131718. https:\/\/doi.org\/10.1093\/annonc\/mdu035","journal-title":"Ann Oncol"},{"key":"10354_CR48","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184. https:\/\/doi.org\/10.1200\/JCO.2005.09.102","journal-title":"J Clin Oncol"},{"key":"10354_CR49","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ejca.2008.11.021","volume":"45","author":"G von Minckwitz","year":"2009","unstructured":"von Minckwitz G, Schwenkglenks M, Skacel T, Lyman GH, Pousa AL, Bacon P, Easton V, Aapro MS (2009) Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. Eur J Cancer 45:608\u2013617. https:\/\/doi.org\/10.1016\/j.ejca.2008.11.021","journal-title":"Eur J Cancer"},{"key":"10354_CR50","doi-asserted-by":"publisher","first-page":"119","DOI":"10.18553\/jmcp.2023.29.2.119","volume":"29","author":"CY Wang","year":"2023","unstructured":"Wang CY, Vouri SM, Park H, Heldermon CD, Brown JD (2023) Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: a retrospective cohort study. J Manag Care Spec Pharm 29:119\u2013127. https:\/\/doi.org\/10.18553\/jmcp.2023.29.2.119","journal-title":"J Manag Care Spec Pharm"},{"key":"10354_CR51","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/03007995.2017.1386858","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Lonshteyn A, Doroff R, Chandler D (2017) Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015. Curr Med Res Opin 33:2107\u20132113. https:\/\/doi.org\/10.1080\/03007995.2017.1386858","journal-title":"Curr Med Res Opin"},{"key":"10354_CR52","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1080\/03007995.2017.1386638","volume":"33","author":"D Weycker","year":"2017","unstructured":"Weycker D, Bensink M, Wu H, Doroff R, Chandler D (2017) Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis based on real-world data from 2010 to 2015. Curr Med Res Opin 33:2115\u20132120. https:\/\/doi.org\/10.1080\/03007995.2017.1386638","journal-title":"Curr Med Res Opin"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10354-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:06:24Z","timestamp":1771272384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10354"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10354-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This observational study complied with the principles set out in the current version of the Declaration of Helsinki and was approved by the ethical committee of the \u00c4rztekammer Nordrhein (ID 2018375). It was registered in the German Clinical Trial Register (ID DRKS00017218).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"T Steinmetz received research funding from Accord Healthcare, Amgen, Celgene\/BMS, is a member of the board of directors, speaker\u2019s bureau or advisory committee of Accord Healthcare, Amgen, BMS\/Celgene, Hexal\/Sandoz, Janssen-Cilag, Novartis and Pfizer. P Jungberg, D Guth, J Knoblich, T Fietz, T G\u00f6hler, M Reiser; U Totzke received honoraria by Accord Healthcare GmbH; K Bernhardt was\u00a0former employee of Accord Healthcare GmbH. All remaining authors declare they have no financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}